Arch Therapeutics, INC 8-K filings

Arch Therapeutics announces the resignation of CFO Michael Abrams and the appointment of CEO Terrence Norchi as Principal Accounting Officer and Treasurer, effective February 3, 2025.

Arch Therapeutics finalized the tenth closing of its convertible notes offering on January 16, 2025, securing $125,000 in net proceeds for working capital and general corporate purposes.

Arch Therapeutics has completed the ninth closing of its convertible notes offering, securing approximately $100,000 in net proceeds.

Arch Therapeutics has amended several of its outstanding convertible promissory notes, extending their maturity dates from September 30, 2024, to November 30, 2024, and increasing the principal amount of some notes.

Arch Therapeutics has completed the eighth closing of its convertible notes offering, raising an additional $108,000 in net proceeds.

Arch Therapeutics has amended multiple promissory notes and a securities purchase agreement, extending maturity dates and increasing the maximum funding amount.

Arch Therapeutics has completed the seventh closing of its convertible notes offering, raising approximately $108,000 in net proceeds for working capital and general corporate purposes.

Laurence Hicks resigned from the board of directors of Arch Therapeutics, Inc. effective August 28, 2024.

Arch Therapeutics has completed the sixth closing of its convertible notes offering, securing an additional $100,000 in net proceeds.

Arch Therapeutics has amended several of its outstanding convertible promissory notes, extending their maturity dates from August 15, 2024, to September 15, 2024.

Punit Dhillon has resigned from the board of directors of Arch Therapeutics, Inc., effective August 14, 2024.

Arch Therapeutics has completed the fifth closing of its convertible notes offering, raising approximately $80,000 in net proceeds.

Arch Therapeutics has finalized the fourth closing of its convertible notes offering, raising approximately $140,000 for working capital and general corporate purposes.

Arch Therapeutics has amended multiple promissory notes, extending the deadline for an uplist and related repayment provisions from June 30, 2024, to August 15, 2024.

Arch Therapeutics completed a third closing of its convertible note offering, securing an additional $75,000 in net proceeds.

Arch Therapeutics has entered into a backstop agreement to ensure sufficient funding for its planned uplisting and amended its PIPE financing terms.

Arch Therapeutics has completed a second closing of its convertible notes offering, securing $150,000 in net proceeds for working capital and general corporate purposes.

Arch Therapeutics has secured $2.22 million through the issuance of senior secured convertible notes, backed by a security agreement covering substantially all of the company's assets.

Arch Therapeutics has amended multiple agreements, including registration rights and promissory notes, to extend the deadline for an uplist transaction to June 30, 2024.

Arch Therapeutics received a $250,000 advance from certain purchasers under a previous agreement, with potential warrant issuance if certain conditions are not met by April 30, 2024.

Arch Therapeutics has completed a fourth closing of its convertible notes offering, raising approximately $450,000 and has amended the terms of its uplist transaction.

Arch Therapeutics received a $250,000 advance under a previously disclosed Securities Purchase Agreement, with potential warrant issuance if certain conditions are not met by March 31, 2024.

Arch Therapeutics has amended the terms of a prior $500,000 advance and secured an additional $250,000, with the possibility of issuing warrants if certain conditions are not met by March 31, 2024.

Arch Therapeutics has replaced its independent auditor, Baker Tilly, with Weinberg & Company, effective January 9, 2024.

Arch Therapeutics has amended its convertible promissory notes to extend the deadline for an uplist transaction and the maturity dates of the notes to March 15, 2024.